Inability of prostaglandin synthesis inhibitors to affect adipose tissue lipolysis.
D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology*; D004822:Epididymis; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005990:Glycerol / Q000378:metabolism; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology*; D008053:Lipid Mobilization / Q000187:drug effects*; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000096:biosynthesis; D051381:Rats
D001095:Arachidonic Acids; D005230:Fatty Acids, Nonesterified; D005231:Fatty Acids, Unsaturated; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D005990:Glycerol; D009638:Norepinephrine; D007213:Indomethacin